A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV261 Tablets in Chinese Healthy Volunteers
Latest Information Update: 31 Dec 2025
At a glance
- Drugs VV 261 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 31 Dec 2025 New trial record